KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Accured Expenses: 2009-2024

Historic Change in Accured Expenses for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to -$32.2 million.

  • Biomarin Pharmaceutical's Change in Accured Expenses fell 6.82% to $113.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year decrease of 76.14%. This contributed to the annual value of -$32.2 million for FY2024, which is 146.82% down from last year.
  • Biomarin Pharmaceutical's Change in Accured Expenses amounted to -$32.2 million in FY2024, which was down 146.82% from $68.9 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Change in Accured Expenses ranged from a high of $68.9 million in FY2023 and a low of -$87.0 million during FY2020.
  • Moreover, its 3-year median value for Change in Accured Expenses was $59.0 million (2022), whereas its average is $31.9 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Change in Accured Expenses plummeted by 212.89% in 2020 and then surged by 276.17% in 2022.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Accured Expenses (Yearly) stood at -$87.0 million in 2020, then soared by 118.03% to $15.7 million in 2021, then skyrocketed by 276.17% to $59.0 million in 2022, then grew by 16.66% to $68.9 million in 2023, then slumped by 146.82% to -$32.2 million in 2024.